Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUM001 extension in Primary Biliary Cholangitis
NCT02321306Phase 2Withdrawn
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- May 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of maralixibat in primary biliary cholangitis (PBC), sponsored by Mirum Pharmaceuticals, Inc. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety at 2 years. Planned start May 2015; status: withdrawn.
02
Drugs
maralixibat
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT02321306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02321306.